A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Berobenatide or placebo is given by a shot under the skin in the belly area. The objective of the study is to compare the experiences of people receiving berobenatide to those of the people who do not to assess if the study medicine is effective and safe. People will take part in this study for about 20 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.
Sponsor: Pfizer
You may qualify if…
- ✓ Aged ≥18 years.
- ✓ BMI of: ≥30 kg/m2 or ≥27.0 kg/m2 to \<30.0 kg/m2 and must have at least 1 of the following weight-related co-morbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2D.
You may not qualify if…
- ✕ Have a self-reported body weight change greater than 5% within 90 days prior to Screening.
- ✕ Diagnosis of type 1 diabetes or any other form of diabetes other than T2D.
- ✕ History of acute or chronic pancreatitis.
- ✕ Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).
Where it's recruiting
Roseville · Sacramento
Crystal River · Lecanto
Evansville
Albuquerque
Rochester
Cincinnati
Source: ClinicalTrials.gov · NCT07595549 · last updated 2026-06-23